Osiris Will Focus On Liver GvHD While Sorting Data From Failed Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
"The idea of giving up and going home is simply not in the cards," CEO Mills says.
You may also be interested in...
Continued Genzyme Problems Offer Gaucher Opportunity To Competitors
Genzyme's Allston Landing, Mass., plant - currently the only facility that produces its Cerezyme and Fabrazyme drugs - resumed working at full capacity on Aug. 28. But it seems the big biotech's manu-facturing woes are far from over: a mid-August visit by the European Medicines Agency found deficiencies, and a critical FDA inspection is still to come
Osiris Hiccup In COPD Barely Registers In Maturing Stem Cell Sector
The rapidly evolving stem cell space may have matured to the level where a single company’s misstep no longer raises questions about the viability of the whole endeavor. At least that seems to be the reaction following Osiris Therapeutics’ recent announcement that its mesenchymal stem cell therapy Prochymal produced mixed results in an interim look at a study of 62 patients with chronic obstructive pulmonary disease.
Trial Flaw Hold-Up With Osiris' Prochymal In Crohn's Not A Factor In GvHD
Osiris Therapeutics’ decision to stop enrolling Phase III trials with Prochymal in Crohn’s disease does not go far toward predicting outcomes in its lead indication of graft vs. host disease, given the difference between methods of efficacy measurements between the two conditions.